Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma
Boehringer Ingelheim
Boehringer Ingelheim
National Taiwan University Hospital
Institut Bergonié
Dana-Farber Cancer Institute
Eli Lilly and Company
Boehringer Ingelheim
Alliance for Clinical Trials in Oncology
Columbia University
Sarcoma Alliance for Research through Collaboration
Washington University School of Medicine
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
Karyopharm Therapeutics Inc
Northwestern University
Children's Oncology Group
OHSU Knight Cancer Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Massachusetts General Hospital
Vector Oncology
Memorial Sloan Kettering Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
National Cancer Institute (NCI)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
H. Lee Moffitt Cancer Center and Research Institute